June round-up of pharma/biotech M&A activity

5 July 2016

The Brexit risk and reality, and the beginning of the summer slow-down might explain why June was a quieter month than May in pharmaceutical industry deal-making.

That does not mean there have been some deals done and further rumors and posturing over potential takeovers, such as continued news on the $9.3 billion bid from French pharma major Sanofi (Euronext: SAN) of US biotech Medivation (Nasdaq: MDVN), and reports that Ireland-headquartered Perrigo (NYSE: PRGO) was to be bought by a UK-based company.

There has also been the continuing divestment of assets of Israel's Teva Pharmaceutical Industries (NYSE: TEVA) to satisfy the conditions of its $40.5 billion purchase of the generics business of Ireland-incorporated Allergan (NYSE: AGN), with Impax Laboratories USA-based Impax Laboratories (Nasdaq: IPXL) buying a range of products in a $586 million deal. These are not included as actual M&A deals, since thet are only asset purchases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK